Can another lipid, sphingosine-1-phosphate, treat atherosclerosis?

Cardiovasc Res

Division of Endocrinology, New York University Grossman School of Medicine, 435 East 30th Street, SB 617, New York, NY 10016, USA.

Published: April 2024

Download full-text PDF

Source
http://dx.doi.org/10.1093/cvr/cvae050DOI Listing

Publication Analysis

Top Keywords

lipid sphingosine-1-phosphate
4
sphingosine-1-phosphate treat
4
treat atherosclerosis?
4
lipid
1
treat
1
atherosclerosis?
1

Similar Publications

Objectives: Spingosine-1-phosphate (S1P) and ceramides are bioactive sphingolipids that influence cancer cell fate. Anti-ceramide antibodies might inhibit the effects of ceramide. The aim of this study was to assess the potential role of circulating S1P and anti-ceramide antibody as biomarkers in non-small cell lung cancer (NSCLC).

View Article and Find Full Text PDF

Transport and inhibition of the sphingosine-1-phosphate exporter SPNS2.

Nat Commun

January 2025

Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Sphingosine-1-phosphate (S1P) is a signaling lysolipid critical to heart development, immunity, and hearing. Accordingly, mutations in the S1P transporter SPNS2 are associated with reduced white cell count and hearing defects. SPNS2 also exports the S1P-mimicking FTY720-P (Fingolimod) and thereby is central to the pharmacokinetics of this drug when treating multiple sclerosis.

View Article and Find Full Text PDF

Glomerular endothelial cells (GECs) are pivotal in developing glomerular sclerosis disorders. The advancement of focal segmental glomerulosclerosis (FSGS) is intimately tied to disruptions in lipid metabolism. Sphingosine-1-phosphate (S1P), a molecule transported by high-density lipoproteins (HDL), exhibits protective effects on vascular endothelial cells by upregulating phosphorylated endothelial nitric oxide synthase (p-eNOS) and enhancing nitric oxide (NO) production.

View Article and Find Full Text PDF

Diabetes is a significant global health issue, causing extensive morbidity and mortality, and represents a serious threat to human health. Recently, the bioactive lipid molecule Sphingosine-1-Phosphate has garnered considerable attention in the field of diabetes research. The aim of this study is to comprehensively understand the mechanisms by which Sphingosine-1-Phosphate regulates diabetes.

View Article and Find Full Text PDF

Background: Severe disruption of lipid metabolism in vivo is one of the central mechanisms in the development of atherosclerotic vascular injury (AVI). Reverse cholesterol transport (RCT) plays a pivotal role in eliminating excess cholesterol, preventing lipid deposition in the aorta, and reducing plaque formation associated with AVI. Floralozone (FL) reduces endothelial cell injury in AVI rats by regulating sphingosine-1-phosphate (S1P) expression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!